MDWD

MediWound's NexoBrid Shows Significant Beneficial Impact On Pediatric Burn Patients

MDWD Stock Increases Over 15% Pre-Market: Why It Happened

MediWound Announces Peer-Reviewed Paper Detailing EscharEx Phase 2 Randomized Control Trial Results Published in the Online Wound Repair and Regeneration Journal

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MediWound Ltd. - MDWD

MediWound Receives Complete Response Letter from U.S. FDA for NexoBrid Biologics License Application

MediWound Completes Patient Enrollment for Interim Assessment of its U.S. EscharEx Phase 2 Adaptive Design Study